The latest price target for Ironwood Pharmaceuticals (NASDAQ:IRWD) was reported by Leerink Partners on September 9, 2024. The analyst firm set a price target for $5.00 expecting IRWD to rise to within 12 months (a possible 49.70% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Ironwood Pharmaceuticals (NASDAQ:IRWD) was provided by Leerink Partners, and Ironwood Pharmaceuticals initiated their market perform rating.

There is no last upgrade for Ironwood Pharmaceuticals

There is no last downgrade for Ironwood Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ironwood Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ironwood Pharmaceuticals was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest Ironwood Pharmaceuticals (IRWD) rating was a initiated with a price target of $0.00 to $5.00. The current price Ironwood Pharmaceuticals (IRWD) is trading at is $3.34, which is within the analyst’s predicted range.